StudyPages - First in-Human Trial of the Experimental Drug AMG 176 in Relapsed or Refractory (re-occurring) Cancer of the Blood Systems
AstraZeneca Cancer Trial Hit with Clinical Hold Following Cardiac Issues | BioSpace
AMG 176 Myeloma Trials
Cancers | Free Full-Text | Therapeutics Targeting the Core Apoptotic Machinery
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation - ScienceDirect
Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases - eBioMedicine
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapi
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Frontiers | Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
AMG 176 | New Drug Approvals
Accelerated Development of a Scalable Ring-Closing Metathesis to Manufacture AMG 176 Using a Combined High-Throughput Experimentation and Computational Modeling Approach | Organic Process Research & Development
AMG 176 – Drug Approvals International
AMG 176 | New Drug Approvals
AMG176 - Multiple Myeloma Clinical Trials
AMG 176 | New Drug Approvals
Cancers | Free Full-Text | Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
Updates and rationale of clinical trials in multiple myeloma - Branagan - 2019 - ADVANCES IN CELL AND GENE THERAPY - Wiley Online Library
Accelerated Development of a Scalable Ring-Closing Metathesis to Manufacture AMG 176 Using a Combined High-Throughput Experimentation and Computational Modeling Approach | Organic Process Research & Development
:%0A%0AAMG%20176%20for%20Multiple%20Myeloma.png?md=1 "AMG 176 for Multiple Myeloma Clinical Trial 2023 | Power")
AMG 176 for Multiple Myeloma Clinical Trial 2023 | Power
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
Kyprolis-Plus-Darzalex Boosts Amgen's Myeloma Pipeline, After MCL-1 Drugs' Clinical Holds :: Scrip
PDF) Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
AMG-176 | Cas# 1883727-34-1 - GlpBio
Targeting MCL-1 in cancer: current status and perspectives | Journal of Hematology & Oncology | Full Text
